Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Naval Daver

Leukemia · MD Anderson Cancer Center

View

Dr. Daniel Pollyea

Leukemia · CU Anschutz Medical Campus

View

Dr. Jessica Altman

Leukemia · Northwestern Medicine

View

Dr. Shella Saint Fleur-Lominy

Leukemia · UMSOM

View

Dr. Azra Raza

Leukemia · CUIMC

View

Dr. Molly Imgruet

Leukemia · Stanford

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    RCDr. Ryan Cassaday

    Dr. Ryan Cassaday

    Hematology & Oncology · Leukemia
    Fred Hutchinson/University of Washington/Seattle Children’s Cancer Consortium
    ryancassaday

    Research

    Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL

    2026

    Via Blood

    Research

    Patients First: Navigating Asparaginase-Based Treatment in Young Adults With Acute Lymphoblastic Leukemia

    2026

    Via Am J Hematol

    Research

    Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study

    2026

    Via Blood

    Research

    Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia

    2026

    Via Leuk Lymphoma

    Research

    Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms

    2026

    Via Leukemia

    Research

    Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL

    2026

    Via Blood Adv

    Research

    Outcomes by Body Mass Index in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Treated with Inotuzumab Ozogamicin

    2026

    Via Target Oncol

    Research

    Incidence and risk factors for CNS relapse in adult ALL after allogeneic hematopoietic cell transplantation

    2026

    Via Blood Adv

    Research

    Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement

    2025

    Via Blood Adv

    Research

    Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow-up

    2025

    Via Haematologica

    Research

    Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell Therapy

    2025

    Via Transplant Cell Ther

    Research

    Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma

    2025

    Via Br J Haematol

    Research

    The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

    2025

    Via Bone Marrow Transplant

    Research

    Recognition, prevention, and management of adverse events associated with asparaginase/ pegaspargase treatment of acute lymphoblastic leukemia in adults: consensus of an expert panel

    2025

    Via Haematologica

    Research

    Sanctuary sites and extramedullary relapses in the chemo-free world: insights from immunotherapies in B-ALL

    2025

    Via Hematology Am Soc Hematol Educ Program